Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Source: 
Endpoints
snippet: 

Just a few weeks after Vivek Ramaswamy’s Axovant $AXON got a big boost out of its licensing pact with Oxford BioMedica for what is now called AXO-Lenti-PD, a gene therapy designed to spur dopamine production in the brain, the biotech is continuing its makeover with a new deal adding a fresh set of gene therapies to the pipeline.